Shares of Novo Nordisk (NYSE:) and Eli Lilly & Co. (NYSE:) are down premarket Friday as competition in the GLP-1 market. Amgen (NASDAQ:) disclosed that it looked at AMG133’s unblinded phase 2 interim trial and came away confident in 133’s differentiated profile.
AMG 133 is Amgen’s obesity candidate and is currently being assessed in a trial among participants who are overweight or obese, with or without type 2 diabetes.
AMGN reported earnings after the close Friday, with analysts at Deutsche Bank stating that the company “notes 133’s differentiation is relative to currently approved GLP1s and most importantly, those in the pipeline.”
Following the earnings release, LLY shares are down 2.3% premarket, while Novo Nordisk’s ADRs declined 3%.
“133 dominated the Q&A session and rightfully so, there’s so much at stake and left to the imagination until 133’s full Ph2 read out at year-end 24,”…
